Unfortunately, no survival analyses were planned in that study.25 Recently, another work described the relationship between CDX2 and prognosis in CRC: in this study, loss of CDX2 expression was associated with significantly worse OS, but specific analyses for stage IV V600EBRAF patients were not possible due to small sample size.26 According to our data, low CDX2 expression was associated to worse OS (HR of intermediate/low vs high expression = 1.72, 95%CI 1.03–2.86, p = 0.036). Here, CDX2 is linked to colorectal carcinoma.